Nicoya is advancing biopharmaceutical breakthroughs by equipping scientists with a powerful, integrated analytical platform for characterizing complex biologics. Following its acquisition of Applied Photophysics, Nicoya uniquely combines its pioneering Surface Plasmon Resonance (SPR) systems, including the high-throughput Alto™, with world-renowned technologies for protein structural analysis (Chirascan™ Circular Dichroism) and kinetic/stability studies (SX™ stopped-flow, SUPR-DSF™). This unified offering provides researchers with a comprehensive understanding of a biologic's critical quality attributes—function, structure, and stability—from a single, expert source. By enabling earlier, more informed decision-making, and delivering high-quality data crucial for AI-driven drug development, Nicoya empowers partners to de-risk pipelines, accelerate the path to clinic, and bring life-changing therapies to patients more efficiently.